Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium

GlobeNewswire October 4, 2022

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

GlobeNewswire September 29, 2022

aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT(TM) Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

GlobeNewswire September 27, 2022

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

GlobeNewswire September 13, 2022

aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

GlobeNewswire September 6, 2022

aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022

GlobeNewswire September 1, 2022

aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

GlobeNewswire August 15, 2022

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 12, 2022

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

GlobeNewswire August 11, 2022

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

GlobeNewswire June 14, 2022

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

GlobeNewswire June 13, 2022

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

GlobeNewswire May 17, 2022

aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis

GlobeNewswire May 16, 2022

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 13, 2022

aTyr Pharma to Present at Upcoming Investor Conferences in May

GlobeNewswire May 10, 2022

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

GlobeNewswire May 9, 2022

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

GlobeNewswire May 2, 2022

aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis

GlobeNewswire April 13, 2022